138 related articles for article (PubMed ID: 9923819)
1. A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia.
Bernstein SH; Fay J; Frankel S; Christiansen N; Baer MR; Jacobs C; Blosch C; Hanna R; Herzig G
Cancer Chemother Pharmacol; 1999; 43(2):141-4. PubMed ID: 9923819
[TBL] [Abstract][Full Text] [Related]
2. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients.
Takebe N; Paredes J; Pino MC; Lownsbury WH; Agosti J; Krown SE
J Interferon Cytokine Res; 1998 May; 18(5):321-6. PubMed ID: 9620359
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
6. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor.
Mullarkey MF; Leiferman KM; Peters MS; Caro I; Roux ER; Hanna RK; Rubin AS; Jacobs CA
J Immunol; 1994 Feb; 152(4):2033-41. PubMed ID: 8120405
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
[TBL] [Abstract][Full Text] [Related]
8. Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer.
Mantovani G; Macciò A; Lai P; Massa E; Massa D; Mulas C; Succu G; Mudu MC; Manca G; Versace R; Pisano A
J Immunother; 2000; 23(2):267-74. PubMed ID: 10746553
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
10. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
Wielenga JJ; Vellenga E; Groenewegen A; Sonneveld P; Löwenberg B
Leukemia; 1996 Jan; 10(1):43-7. PubMed ID: 8558936
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.
Trehu EG; Mier JW; Dubois JS; Sorce D; Klempner MS; Epstein M; Dinarello CA; Shapiro L; Kappler K; Ronayne L; Atkins MB
Clin Cancer Res; 1996 Aug; 2(8):1341-51. PubMed ID: 9816306
[TBL] [Abstract][Full Text] [Related]
13. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA
Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
Portielje JE; Kruit WH; Schuler M; Beck J; Lamers CH; Stoter G; Huber C; de Boer-Dennert M; Rakhit A; Bolhuis RL; Aulitzky WE
Clin Cancer Res; 1999 Dec; 5(12):3983-9. PubMed ID: 10632329
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
19. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
[TBL] [Abstract][Full Text] [Related]
20. Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2.
Speletas M; Ritis K; Bourikas G
Haematologica; 1996; 81(4):346-8. PubMed ID: 8870381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
